scholarly journals Enteric coating of ibuprofen tablets (200 mg) using an aqueous dispersion system

2010 ◽  
Vol 46 (1) ◽  
pp. 99-107 ◽  
Author(s):  
Rabia Bushra ◽  
Muhammad Harris Shoaib ◽  
Nousheen Aslam ◽  
Zafar Alam Mehmood ◽  
Durriya Hashmat
Keyword(s):  
Adverse Reactions ◽  
Aqueous Dispersion ◽  
Basic Medium ◽  
Enteric Coating ◽  
Compression Process ◽  
Rapid Release ◽  
Dissolution Tests ◽  
Mucosal Lining ◽  
Enteric Coated ◽  
Propionic Acid Derivative

Ibuprofen is a propionic acid derivative that belongs to the class NSAIDs. Major adverse reactions associated with Ibuprofen are related to GIT and include peptic and mucosal ulcers, dyspepsia, severe gastric pain and bleeding, that results in excessive treatment failure. The goal of this study was to develop enteric coated ibuprofen tablets in order to avoid gastric mucosal irritation, diffusion of drug across mucosal lining and to let active ingredient be absorbed easily in small intestine. The formulation was developed and manufactured through the direct compression process, the simplest, easiest and most economical method of manufacturing. Enteric coating was done using an Opadry white subcoating and an aqueous coating dispersion of Acryl-Eze. Enteric coated formulation was subjected to disintegration and dissolution tests by placing in 0.1 M hydrochloric acid for 2 h and then 1 h in phosphate buffer with a pH of 6.8. About 0.04% of drug was released in the acidic phase and 99.05% in the basic medium. These results reflect that ibuprofen can be successfully enteric coated in order to prevent its release in the stomach and facilitate rapid release of the drug in the duodenum, due to the presence of superdisintegrant. Formulating this enteric coated tablets could increase patient compliance by decreasing adverse drug reactions (ADR S) associated with Ibuprofen therapy.

scholarly journals Preparation and Characterization of a Novel Aqueous Dispersion for Enteric Coating of Pantoprazole Sodium Pellets

2018 ◽  
Vol 68 (4) ◽  
pp. 441-455 ◽  
Author(s):  
Min Han ◽  
Qin Yu ◽  
Xuerong Liu ◽  
Fuqiang Hu ◽  
Hong Yuan
Keyword(s):  
Spray Coating ◽  
Acid Tolerance ◽  
Aqueous Dispersion ◽  
The Novel ◽  
Enteric Coating ◽  
Coating Technology ◽  
Enteric Coated ◽  
Free Films ◽  
Better Than

Abstract The purpose of this work was to investigate a novel aqueous dispersion (Eudragit® L100-55) f or e nteric c oating o f drugs. Three different casting solutions, Eudragit® L100-55 aqueous dispersion, Eudragit® L 100-55 o rganic s olution, and Eudragit® L30D-55 aqueous dispersion, were used to prepare free films by the casting method. Drug-loaded pellets, prepared by the extrusion-spheronization method, were coated with one of these three coating solutions using the fluidized-bed spray coating technology. Properties of the free films were thoroughly investigated. Films formed by Eudragit® L100-55 aqueous dispersions showed similar properties to those formed by Eudragit® L100-55 organic solution regarding thermodynamic properties, moisture permeability, solubility and acid tolerance ability. Furthermore, the performance of the novel film was better than that formed by Eudragit® L30D-55 aqueous dispersion. Among the three enteric coating solutions, Eudragit® L100- 55 aqueous dispersion will be a promising aqueous dispersion for enteric coating and can be used in the development of enteric-coated preparations.

A Review on Enteric Coated Pellets Composed of Core Pellets Prepared by Extrusion-Spheronization

2019 ◽  
Vol 13 (2) ◽  
pp. 83-90 ◽  
Author(s):  
Hetal Patel ◽  
Mukesh Gohel
Keyword(s):  
Dosage Form ◽  
Extended Release ◽  
Rapid Onset ◽  
Enteric Coating ◽  
Onset Of Action ◽  
The Core ◽  
Current State ◽  
Enteric Coated ◽  
Extrusion Spheronization ◽  
Acid Labile

Enteric coated dosage form bypasses the stomach and releases the drug into the small intestine. Advantages of enteric coated pellets in comparison with enteric coated tablets are a) Pellets provide rapid onset of action and faster drug release due to the smaller size than tablets and b) Pellets exhibit less residence time of acid-labile drugs in the stomach compared to tablets. Dosage form coat can be damaged by longer resistance time in the stomach. The present review summarizes the current state of enteric coated pellets where core pellets are prepared by extrusion-spheronization technique and the enteric coating is applied in a fluidized bed processor. Two approaches are involved in the preparation of core pellets. In the first approach, a mixture of drug and excipient(s)/co-processed excipient is passed through extruders to prepare core pellets. In the second approach, excipient core pellets are prepared by extrusion technique and the drug is layered onto it before the enteric coating. The excipients present in the core pellets decide immediate or extended release of drug in the intestine. The coprocessed excipient pellets provide less batch variability and provide a platform for layering of many drugs before enteric coating. Some patents included enteric coating pellets [CN105456223 (A), CN105596310 (A), CN105616371 (A), CN105663095 (A), CN101611766B, CN106511862 (A), CN106668018 (A), CN106727381 (A), CN106924222 (A), TW200624127 (A), US 2017/0165248A1, US 2017/0224720A1] are discussed.

scholarly journals FORMULATION OF RIZATRIPTAN BENZOATE SUBLINGUAL TABLETS PREPARED BY DIRECT COMPRESSION WITH DIFFERENT BIOADHESIVE POLYMER: IN VITRO AND EX VIVO EVALUATION

2017 ◽  
Vol 10 (16) ◽  
pp. 36
Author(s):  
Harmanpreet Singh ◽  
Pooja Jaiswal ◽  
Suksham Gupta ◽  
Simerjit Singh
Keyword(s):  
Ex Vivo ◽  
Methyl Cellulose ◽  
Systemic Circulation ◽  
Direct Compression ◽  
Compression Process ◽  
Rizatriptan Benzoate ◽  
Dissolution Tests ◽  
Ex Vivo Permeation ◽  
Bioadhesive Polymers

  Objective: The current investigation deals with formulation and evaluation of fast disintegrating sublingual tablets of rizatriptan benzoate (RTB) to produce its intended therapeutic effect for acute treatment of migraine. When the drug is given by sublingual route, it overcomes the first pass metabolism and quick entry of drug in systemic circulation is obtained. It would result in fast pharmacological response hence faster relief from migraine which is an important criterion in migraine therapy.Methods: In this study, RTB sublingual tablets were prepared using direct compression process using various bioadhesive polymers such as sodium carboxymethyl cellulose, hydroxyl propyl methyl cellulose-K4M, and chitosan at various concentration ranging 0.5-5% w/w along with sodium starch glycolate (SSG) or cross carmellose sodium (CCS) as super disintegrants at different concentration ranging 2-8% w/w.Results: The tablets disintegrated quickly and dissolution tests conclude that RTB was released from the formulation within the compendial limits. The formulations batches (A8 and B8) containing 2% w/w chitosan along with 2% w/w SSG or CCS which disintegrate rapidly and show high dissolution and ex vivo permeation were selected as optimized formulations.Conclusion: The results obtained from the study showed that the bioavailability problem of the drug has been solved as the drug is given by sublingual route and it directly enters into systemic circulation. Furthermore, the formulation overcomes the problems associated with migraine attack as fast disintegrating technology is used.

Impact of pharmaceutical dosage form on stability and dissolution of roxithromycin

Open Medicine ◽  
2010 ◽  
Vol 5 (1) ◽  
pp. 83-90 ◽  
Author(s):  
Michał Ostrowski ◽  
Ewa Wilkowska ◽  
Tomasz Bączek
Keyword(s):  
High Performance ◽  
Bitter Taste ◽  
Immediate Release ◽  
Oral Suspension ◽  
Pharmaceutical Dosage Form ◽  
Dissolution Tests ◽  
Ph Conditions ◽  
Dispersible Tablets ◽  
Enteric Coated

AbstractThe behavior of dispersible tablets containing enteric-coated pellets and oral suspension, both containing roxithromycin, was investigated using dissolution tests in different media. The dissolution test was performed under different pH conditions. For both dosage forms investigated, the test was conducted at pH 1.2, 4.5, and 6.8. Additionally, for dispersible tablets, the test involving increasing pH was performed at pH 1.2 (acid stage) and afterwards at pH 6.8 (buffer stage). The extent of dissolution was measured using high-performance liquid chromatography (HPLC). In all cases tested, roxithromycin underwent rapid degradation at pH 1.2. Dispersible tablets displayed the features of modified release preparations with a non-complete dissolution during the test times in all media. Conversely, the oral suspension behaved as an immediate release preparation, with degradation at pH 1.2. However, the dissolution of the oral suspension at pH 4.5 and 6.8 was rapid and complete. The role of enteric-coated pellets is to mask the bitter taste of the active substance upon administration. However, the coating showed lack of resistance to media at pH 1.2. Therefore, dispersible tablets containing enteric-coated pellets are not pharmaceutically equivalent to the immediate-release oral suspension.

scholarly journals Effect of Dissolving pH of Enteric Coating Agent on Bioavailability of Enteric Coated Tablets of Erythromycin in Man

1978 ◽  
Vol 98 (8) ◽  
pp. 1092-1100 ◽  
Author(s):  
YASUSHI WATANABE ◽  
MICHIO SANO ◽  
KIYOSHI MOTOHASHI ◽  
RYOZO YONEDA
Keyword(s):  
Enteric Coating ◽  
Coating Agent ◽  
Enteric Coated

scholarly journals FORMULATION AND EVALUATION OF PRESS COATED TABLETS OF LANSOPRAZOLE

2019 ◽  
pp. 49-56
Author(s):  
Prasanthi D ◽  
PRASHANTI. S ◽  
MEGHANA G
Keyword(s):  
Ethyl Cellulose ◽  
Chemical Properties ◽  
Enteric Coating ◽  
Scanning Calorimetry ◽  
Dsc Studies ◽  
Delayed Release ◽  
Ich Guidelines ◽  
Physico Chemical ◽  
Enteric Coated ◽  
Core Tablet

Objective: Lansoprazole an proton pump inhibitor, degrades in acidic environment, hence protection of drug is done by coating the drug with enteric coating polymers. The aim and objective of the present study was to prepare enteric coated delayed release tablets of lansoprazole by using press coating technique. Methods: Core tablets were prepared by direct compression and evaluated for their physico-chemical properties. Press coated tablets were formulated by using different combinations of ethyl cellulose, HPMC E15 and HPMC K4M as a coating layer. Core and coated tablets were optimized by dissolution studies. Fourier transform infra-red spectroscopy (FTIR) and differential scanning calorimetry (DSC) studies were performed to know the compatibility of drug with various excipients. Surface morphology and uniformity of coat was evaluated by Scanning electron microscopy (SEM). Stability of optimized formulation was evaluated according to ICH guidelines. Results: Among the various formulations F5 containing ethyl cellulose: HPMC E15 (10:90) and F9 containing ethyl cellulose: HPMC K4M (25:75) were optimized based on the better drug release within 8 h. DSC studies and FTIR studies revealed compatibility of drug with excipients. Obtained SEM photographs of tablets showed that the surface of core tablet is uniformly coated with coat by press coating. Stability studies showed that the formulations were stable. Conclusion: As a result, delayed release press coated tablets developed in this study delivered lansoprazole in the intestine and protected the drug from degradation.

Salazopyrin en-tabs: an enteric-coated case that is hard to take

1987 ◽  
Vol 25 (14) ◽  
pp. 53.2-55
Keyword(s):  
Rheumatoid Arthritis ◽  
Ulcerative Colitis ◽  
Clinical Trials ◽  
Enteric Coating ◽  
Disease Modifying ◽  
Enteric Coated ◽  
Established Treatment

Sulphasalazine (Salazopyrin - Pharmacia) has been an established treatment for ulcerative colitis (UC) for over 20 years. More recently its value as a disease-modifying drug in rheumatoid arthritis (RA) has become recognised again.1 All the clinical trials of the drug in RA have employed enteric-coated Salazopyrin EN-tabs rather than the plain tablets usually used in UC. The manufacturer emphasises that only this preparation (and not the plain tablets) ‘is indicated and approved for use in RA’. Why is the enteric coating essential in the treatment of RA but not in ulcerative colitis?

scholarly journals Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
M. Yasmin Begum ◽  
Ali Alqahtani ◽  
Mohammed Ghazwani ◽  
Noura Abdullah Alhamood ◽  
Umme Hani ◽  
...  
Keyword(s):  
Toxic Substance ◽  
Dip Coating ◽  
Gastric Fluid ◽  
Dissolution Profile ◽  
Enteric Coating ◽  
Compression Technique ◽  
Duloxetine Hydrochloride ◽  
Enteric Coated ◽  
The One

The purpose of the research was to optimize the preparation of duloxetine hydrochloride (duloxetine HCl) delayed release tablets. Duloxetine HCl produces a toxic substance called alpha-naphthol when duloxetine HCl is in contact with gastric fluid. Thus, duloxetine HCl when given orally needed a protective enteric coating that disable the delivery of duloxetine HCl in gastric fluid while enabling the drug delivery only in small intestine. Four different core tablets were prepared by direct compression technique, and the one which displayed quick disintegration and dissolution was chosen for enteric coating. The compressed tablets were enteric coated by dip coating technique. Since subcoating is required to safeguard the enteric coating, the core tablets were subcoated by using polymer HPMC K15M and then enteric coated with Eudragit L 100. The prepared tablets were assessed for the entire precompression and postcompression characteristics. FTIR study revealed the existence of all prominent peaks signifying its compatibility and authenticity. The in vitro studies showed that enteric-coated tablets were capable of restricting release in acidic media. The formulation F8 was optimised with 5% and 15% increase in weight of seal coat and enteric coat with good dissolution profile. Stability studies revealed that the optimized formulation was intact without any deterioration for 3 months. In conclusion, the optimized formulation could resist the drug release in acidic environment of gastrointestinal region and release the drug at a time once the tablet reaches the intestine.

scholarly journals Enteric coating of granules containing the probiotic Lactobacillus acidophilus

2014 ◽  
Vol 64 (2) ◽  
pp. 247-256 ◽  
Author(s):  
Hassan Pyar ◽  
Kok-Khiang Peh
Keyword(s):  
Gastric Juice ◽  
Lactobacillus Acidophilus ◽  
Corn Starch ◽  
Viable Cell ◽  
Enteric Coating ◽  
Capsule Formulation ◽  
Disintegration Time ◽  
Enteric Polymer ◽  
Cheap Alternative ◽  
Enteric Coated

Abstract In the present study, a capsule formulation composed of enteric coated granules of Lactobacillus acidophilus ATCC 4962 was developed using Eudragit L30D-55 as enteric polymer. Optimization of the capsule formulation was achieved with a maximum viable cell count after 2 h of incubation in acid medium and disintegration time of 1 h in buffer pH 6.8. The amount of Eudragit L30D-55 in the capsules correlated with gastric juice resistance. The best protective qualities against artificial gastric juice were observed when capsules were prepared from granules composed of L. acidophilus, corn starch, lactose monohydrate, polyvinylpyrrolidone and coated with 12.5 % (m/V) of Eudragit L30D-55. Capsule formulation of L. acidophilus in edible broth medium suspension serves as a cheap alternative to the expensive freeze-drying procedure for preparing L. acidophilus. In addition, the enteric coating using Eudragit L30D-55 could protect probiotics from the acidic gastric environment and enhance the bioactivity of probiotics along with replacement of pathogenic microbes in human intestine

Sign in / Sign up

Export Citation Format

Share Document